Taking together, these data suggest that overexpression of ALDOA in PDA cells is responsible for increased glycolysis, high metastasis, a low survival rate and poor prognosis; thus, the possibility to target ALDOA in order to hinder the glycolysis pathway was investigated. The gene discussed is ALDOA; the disease is Patent ductus arteriosus.